Reliability note

Titles and AI summaries are unofficial English monitoring aids, not legal advice or official translations. Each link opens the original Japanese official source, which remains authoritative.

PMDA announcement: nitrosamine detection in sertraline and telmisartan tablets

「ニトロソアミン化合物検出のお知らせ(セルトラリン錠、テルミサルタン錠)」を掲載しました

Published: 2026-11-10 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Low · First detected by this dashboard: 2026-11-11

View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard

AI summary

Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.

Summary

On 2026-11-10, the Pharmaceuticals and Medical Devices Agency (PMDA) announced publication of nitrosamine-detection notices for sertraline and telmisartan tablets. The linked page lists sertraline 25 mg and 50 mg tablets labeled Towa, and telmisartan 20 mg, 40 mg and 80 mg tablets labeled Felzen, Sandoz and Meiji. The page explains that the Ministry of Health, Labour and Welfare previously notified pharmaceutical marketing authorization holders to conduct nitrosamine-contamination risk self-inspections; the accompanying Q&A describes prompt reporting and risk-reduction measures when testing confirms contamination above applicable limits. The supplied excerpts do not establish the detected compounds, concentrations, affected batches or recall status of these specific products.

Business Impact

Marketing authorization holders for the listed sertraline and telmisartan products may need to assess the product-specific notices against their nitrosamine risk assessments and testing records. Medical institutions receiving these product communications may find information relevant to their handling of the named medicines, but the excerpts do not establish any product-specific action.

Recommended Action

A review could check the individual detection notices for the compound identified, measured level, affected batches and any stated response. Marketing authorization holders could also compare any confirmed findings with the Q&A's reporting and risk-reduction provisions for results exceeding applicable limits.